👉New AGA Clinical Practice Update: Cancer Screening and Vaccinations in Patients with Inflammatory Bowel Disease 🧮13 helpful reminders for healthcare maintenance in #IBD care https://t.co/GGZpRcxDAF

#CGH4ALL How does efficacy of upadacitinib for Crohn's disease differ amongst patients with or without prior biologic failure❓ ▶️Post-Hoc analysis of U-EXCEL, U-EXCEED & U-ENDURE trials 🔖 in @AGA_CGH 📣 🔗 https://t.co/6evCfL8wW4 reported by @NAggarwalMD

Update on biliary pancreatitis #UEGWeek by Marco Bruno @my_ueg 1️⃣ The myth 2️⃣ Defintions of cholestasis / cholangitis 3️⃣ APEC trial 4️⃣ Conclusion - don’t rush into ERCP unless cholangitis

@MondayNightIBD 🎯 #SEAVUE & #SEQUENCE: A #Back2Basics🧵on how we can apply the results of these comparative studies in the management of #Crohns patients in our practice. #MNIBDxEBGI

Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn’s Disease: A Post Hoc Analysis of 3 Phase 3 Trials - ⁦@AGA_CGH⁩

Slides from #AGW24 talk on Acute Severe UC https://t.co/iPPtMGarjO

**THE PREDICT STUDY** These are the questions the PREDICT-UC group out of Australia sought to address! The first question: Does the initial dosing of IFX in ASUC (5mg/kg vs 10mg/kg) matter? The second question: does shortening the interval between IFX infusions and providing

🔥Emoroid Digest🔥 Explore the visual summary by @ct1_cynthia on the latest @amergastroassn best practice advice for the diagnosis, treatment, and long-term management of patients with acute hepatic porphyrias. @AASLDFoundation @Porphyria_Help @BPA_Porphyria @AmCollegeGastro

Let’s aim for a steroid-free future to treat #autoimmunehepatitis! Read about treatments in development for #AIH in @HepCommJournal [ https://t.co/0dzN35HlWj]. #openacess @KezarBio

Everything you need to know about complementary and alternative medicine and the liver Massive review from @theliverdr in @HepCommJournal Open access https://t.co/CsQtJAFAal #livertwitter

📣 💥 Opportunity to be the next #IBD fellow to join our team at @IbdHull to horne your skills in complex #IBD management and develop research 🔬🧐 skills Friendly integrated clinical and research #IBD team 👇 DMs open. Please retweet 🙏🏼 https://t.co/j0of5eJluD

All of our experts' reports from #ECCO24 are now available on #high5immunologyTV! The latest findings on #gastroenterology #IBD #ulcerative #colitis #Crohnsdisease and more free and on-demand!

An easy way to remember serum protein electrophoresis for #MedstudentTwitter ! In myeloma, the thumb goes ⤴️ and the pinky finger goes ⤵️ To know more than this, follow along 👇🏼 #MedTwitter 1/16

Dear all @ibdseb is great candidate for treasurer post in #ECCO governing body With his experience, energy & visions he will contribute to push the ECCO REACH goals Let us support him @ESCP_studies @OPSORE

Upadacitinib for acute severe UC • n is 25 • strange %'s in abstract • @AmJGastro website down @ibddoctor can you share ms please

Excited to share the insights of the retrospective, multicentric PORCSE study considering prevention of POR and treatment burden after ICR for Crohn’s! Prophylaxis for all?! Big shoutout to a fantastic European collab team | Journal of Crohn’s and Colitis https://t.co/4egqbf0liC

Absolutely agree 💯

Rectal treatments for #IBD #UlcerativeColitis can be an effective choice for patients with more distal disease yet some may find them difficult to manage Our video presented by a #GI consultant provides a simple guide to self-administering mesalazine foam https://t.co/obSFbNUkFT

Highlighting 2023 papers in IBD from Gastroenterology. Studies crossed all pillars of research from translational to clinical to population health. Improved our understanding of IBD and expanded the horizon of clinical practice. @AGA_Gastro @PaulMoayyedi @h_sokol @Iris_Dotan /1